No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors

Journal of Infection

Volumn 74, Issue 4, 2017, Pages 393-400

  Woestenberg, Petra J ^a   King, Audrey J ^a   van der Sande, Marianne A B ^a   Donken, Robine ^a   Leussink, Suzan ^a   van der Klis, Fiona R M ^a   Hoebe, Christian J P A ^a   Bogaards, Johannes A ^a   van Benthem, Birgit H B ^a   Adema, D ^{b,e,g,aa,ab,ac}   Buist Arkema, R ^{b,e,g,aa,ab,ac}   Beerens, A ^{b,e,g,aa,ab,ac}   Luijt, D ^{b,e,g,aa,ab,ac}   Meijer, S ^{b,e,g,aa,ab,ac}   Schirm, J ^{b,e,g,aa,ab,ac}   Buiting, A ^{c,e,g,aa,ab,ac}   Peeters, M ^{c,e,g,aa,ab,ac}   Rossen, J ^{c,e,g,aa,ab,ac}   Verbakel, H ^{c,e,g,aa,ab,ac}   van Esch, P ^{c,e,g,aa,ab,ac}   Verweij, J ^{c,e,g,aa,ab,ac}   van der Eijk, A ^{d,e,g,aa,ab,ac}   Huisman, R ^{d,e,g,aa,ab,ac}   Kerkhof, C ^{d,e,g,aa,ab,ac}   Korff, H ^{d,e,g,aa,ab,ac}   Schutten, M ^{d,e,g,aa,ab,ac}   Velzing, J ^{d,e,g,aa,ab,ac}   Verduyn Lunel, F ^e,g,aa,ab,ac   Lakbiach, S ^e,g,aa,ab,ac   van Rosmalen, P ^e,g,aa,ab,ac   Schuurman, R ^e,g,aa,ab,ac   Abma, D ^{e,f,g,aa,ab,ac}   Adams, K ^{e,f,g,aa,ab,ac}   Bruisten, S ^{e,f,g,aa,ab,ac}   Linde, I ^{e,f,g,aa,ab,ac}   Oostvogel, P ^{e,f,g,aa,ab,ac}   Touwen, C ^{e,f,g,aa,ab,ac}   Vermeulen, W ^{e,f,g,aa,ab,ac}   Brink, A ^e,g,aa,ab,ac   Nelissen, J ^e,g,aa,ab,ac   Wolffs, P ^e,g,aa,ab,ac   Duijvendijk, N ^{e,g,h,aa,ab,ac}   Schneeberger, P ^{e,g,h,aa,ab,ac}   Dinnissen van Poppel, M ^{e,g,i,aa,ab,ac}   Melchers, W ^{e,g,i,aa,ab,ac}   Poort, Y ^{e,g,i,aa,ab,ac}   Hooghiemstra, M ^{e,g,j,aa,ab,ac}   Huisman, H ^{e,g,j,aa,ab,ac}   Weel, J ^{e,g,j,aa,ab,ac}   Bosch, H ^{e,g,k,aa,ab,ac}   de Haas, T ^{e,g,k,aa,ab,ac}   Kleinspenkelink, R ^{e,g,k,aa,ab,ac}   Polman, I ^{e,g,k,aa,ab,ac}   Smits, T ^{e,g,k,aa,ab,ac}   van Goor, P ^{e,g,l,aa,ab,ac}   Wolfhagen, M ^{e,g,l,aa,ab,ac}   de Mooij, C ^{e,g,m,aa,ab,ac}   van Koolwijk, E ^{e,g,m,aa,ab,ac}   Peters, M ^{e,g,m,aa,ab,ac}   Swanink, C ^{e,g,m,aa,ab,ac}   Tiemessen, R ^{e,g,m,aa,ab,ac}   van Zwet, T ^{e,g,m,aa,ab,ac}   Janssen, J ^{e,g,n,aa,ab,ac}   Pelsers, M ^{e,g,n,aa,ab,ac}   de Waal, W ^{e,g,o,aa,ab,ac}   Aalfs, G ^{a,e,g,p,aa,ab,ac}   Kiewiet, J ^{a,e,g,p,aa,ab,ac}   Sanders, P ^{a,e,g,p,aa,ab,ac}   van Buel Bruins, H ^{a,e,g,q,aa,ab,ac}   van Bokhoven Rombouts, C ^{a,e,g,r,aa,ab,ac}   Cornelissen, P ^{a,e,g,r,aa,ab,ac}   Kersten, M ^{a,e,g,r,aa,ab,ac}   van Ruitenbeek, C ^{a,e,g,r,aa,ab,ac}   Molenaar, I ^{a,e,g,r,aa,ab,ac}   Doorn, E ^{a,e,g,aa,ab,ac}   Masthoff, L ^{a,e,g,aa,ab,ac}   Pannekoek, E ^{a,e,g,aa,ab,ac}   Sigurdsson, V ^{a,e,g,aa,ab,ac}   Gotz H ^{a,e,g,s,aa,ab,ac}   Illidge Onder de Linden, M ^{a,e,g,s,aa,ab,ac}   Mattijssen, M ^{a,e,g,s,aa,ab,ac}   Stam, J ^{a,e,g,s,aa,ab,ac}   Swaders, E ^{a,e,g,s,aa,ab,ac}   de Groot, F ^{a,e,g,t,aa,ab,ac}   Postma, F ^{a,e,g,t,aa,ab,ac}   Brouwers, E ^{a,e,g,u,aa,ab,ac}   Niekamp, A ^{a,e,g,u,aa,ab,ac}   Smit, M ^{a,e,g,u,aa,ab,ac}   Botraby, A ^{a,e,g,v,aa,ab,ac}   Bukasa, D ^{a,e,g,v,aa,ab,ac}   de Haan, C ^{a,e,g,v,aa,ab,ac}   Hut van Vliet, P ^{a,e,g,v,aa,ab,ac}   Taconis, T ^{a,e,g,v,aa,ab,ac}   de Graas, M ^{a,e,g,w,aa,ab,ac}   Hondelink, I ^{a,e,g,w,aa,ab,ac}   Kampman, C ^{a,e,g,w,aa,ab,ac}   Gelissen Hansen, A ^{a,e,g,x,aa,ab,ac}   de Koning, I ^{a,e,g,x,aa,ab,ac}   van Kruchten, H ^{a,e,g,x,aa,ab,ac}   van de Pas, M ^{a,e,g,x,aa,ab,ac}   Fennema, H ^{a,e,g,y,aa,ab,ac}   Heijman, T ^{a,e,g,y,aa,ab,ac}   Hogewoning, A ^{a,e,g,y,aa,ab,ac}   van Leeuwen, A ^{a,e,g,y,aa,ab,ac}   van Rooijen, M ^{a,e,g,y,aa,ab,ac}   Neienhuijsen, F ^{a,e,g,z,aa,ab,ac}   Pelgrim, M ^{a,e,g,z,aa,ab,ac}   more..

^a Certe ^*

^b Certe Afd Medische Microbiologie   (Netherlands)

^c ETZ Hospital Tilburg   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f Public Health Laboratory Amsterdam   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h JEROEN BOSCH HOSPITAL   (Netherlands)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j Izore   (Netherlands)

^k Lab Mic TA   (Netherlands)

^l Isala   (Netherlands)

^m Rijnstate   (Netherlands)

ⁿ Medical Laboratory Dr Stein College   (Netherlands)

^o CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^p PHS Drenthe   (Germany)

^q PHS IJsselland   (Netherlands)

^r PHS Gelderland Zuid   (Netherlands)

^s Rotterdam Rijnmond Police Department   (Netherlands)

^t PHS Groningen   (Netherlands)

^u PHS Zuid Limburg   (Netherlands)

^v PHS Fryslân   (Netherlands)

^w PHS Twente   (Netherlands)

^x PHS Hart voor Brabant   (Netherlands)

^y Amsterdam   (Netherlands)

^z PHS Gelderland Midden   (Netherlands)

^aa NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^ab VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^ac South Limburg Public Health Service   (Netherlands)

more..

Author keywords

Condylomata acuminata; Human papillomavirus 11; Human papillomavirus 6; Human papillomavirus vaccine, L1 type 16, 18; Prevention control; Vaccination; Warts

Indexed keywords

PLACEBO; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ADULT; ARTICLE; CHLAMYDIASIS; CONCURRENT SEXUAL PARTNERSHIP; CONDOM USE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SURVEILLANCE; DNA EXTRACTION; EDUCATION; ETHNICITY; FEMALE; GONORRHEA; HIGH RISK BEHAVIOR; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; NETHERLANDS; PREVALENCE; SENSITIVITY ANALYSIS; SEXUALLY TRANSMITTED DISEASE; UNITED KINGDOM; VACCINATION; VAGINA SMEAR; VIRUS LIKE AGENT; ADOLESCENT; CONDYLOMATA ACUMINATA; CROSS PROTECTION; IMMUNOLOGY; OUTPATIENT DEPARTMENT; PAPILLOMAVIRUS INFECTIONS; SEXUALLY TRANSMITTED DISEASES; UTERINE CERVICAL NEOPLASMS; VAGINA; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AMBULATORY CARE FACILITIES; CONDYLOMATA ACUMINATA; CROSS PROTECTION; CROSS-SECTIONAL STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SEXUALLY TRANSMITTED DISEASES; UNITED KINGDOM; UTERINE CERVICAL NEOPLASMS; VAGINA; YOUNG ADULT;

EID: 85011841066     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2017.01.007     Document Type: Article

References (29)

1. 1 de Sanjose, S., Quint, W.G., Alemany, L., Geraets, D.T., Klaustermeier, J.E., Lloveras, B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:11 (2010), 1048–1056, 10.1016/S1470-2045(10)70230-8.
2. 2 Garland, S.M., Steben, M., Sings, H.L., James, M., Lu, S., Railkar, R., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 199:6 (2009), 805–814, 10.1086/597071.
3. 3 Paavonen, J., Naud, P., Salmeron, J., Wheeler, C.M., Chow, S.N., Apter, D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:9686 (2009), 301–314, 10.1016/S0140-6736(09)61248-4.
4. 4 Future I/II Study Group, Dillner, J., Kjaer, S.K., Wheeler, C.M., Sigurdsson, K., Iversen, O.E., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ, 341, 2010, c3493, 10.1136/bmj.c3493.
5. 5 Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372:8 (2015), 711–723, 10.1056/NEJMoa1405044.
6. 6 Szarewski, A., Skinner, S.R., Garland, S.M., Romanowski, B., Schwarz, T.F., Apter, D., et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis 208:9 (2013), 1391–1396, 10.1093/infdis/jit360.
7. 7 Howell-Jones, R., Soldan, K., Wetten, S., Mesher, D., Williams, T., Gill, O.N., et al. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis 208:9 (2013), 1397–1403, 10.1093/infdis/jit361.
8. 8 Canvin, M., Sinka, K., Hughes, G., Mesher, D., Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect, 2016, 10.1136/sextrans-2016-052626.
9. 9 de Melker, H.E., Conyn-van Spaendonck, M.A., Boot, H.J., Coutinho, R.A., [Introduction to vaccination against cervical cancer]. Ned Tijdschr Geneeskd 153:14 (2009), 658–661.
10. 10 van Lier, E.A., Oomen, P.J., Giesbers, H., Drijfhout, I.H., de Hoogh, P.A.A.M., de Melker, H.E., [Vaccination coverage National Immunization Program the Netherlands, report year 2011]. 2011, RIVM, Bilthoven [Dutch] 210021014/2011.
11. 11 van Lier, E.A., Oomen, P.J., Giesbers, H., van Vliet, J.A., Drijfhout, I.H., Zonnenberg-Hoff, I.F., et al. [Vaccination coverage National Immunization Program the Netherlands, report year 2016]. 2016, RIVM, Bilthoven [Dutch] 2016-0064.
12. 12 Vriend, H.J., Boot, H.J., van der Sande, M.A., Type-specific human papillomavirus infections among young heterosexual male and female STI clinic attendees. Sex Transm Dis 39:1 (2012), 72–78, 10.1097/OLQ.0b013e318235b3b0.
13. 13 Vriend, H.J., Bogaards, J.A., van der Klis, F.R., Scherpenisse, M., Boot, H.J., King, A.J., et al. Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection. PLoS One, 8(4), 2013, e60696, 10.1371/journal.pone.0060696.
14. 14 Scherpenisse, M., Mollers, M., Schepp, R.M., Boot, H.J., de Melker, H.E., Meijer, C.J., et al. Seroprevalence of seven high-risk HPV types in the Netherlands. Vaccine 30:47 (2012), 6686–6693, 10.1016/j.vaccine.2012.08.068.
15. 15 Donken, R., Schurink-van 't Klooster, T.M., King, A.J., Woestenberg, P.J., Rog, P., Suijkerbuijck, A.W.M., et al. Human papillomavirus (HPV) infection. Schurink-van't Klooster, T.M., de Melker, H.E., (eds.) The National Immunisation Programme in the Netherlands – surveillance and developments in 2014–2015, 2015, RIVM, Bilthoven, 127–138.
16. 16 Woestenberg, P.J., van Oeffelen, A.A., Stirbu-Wagner, I., van Benthem, B.H., van Bergen, J.E., van den Broek, I.V., Comparison of STI-related consultations among ethnic groups in the Netherlands: an epidemiologic study using electronic records from general practices. BMC Fam Pract, 16, 2015, 70, 10.1186/s12875-015-0281-2.
17. 17 Naud, P.S., Roteli-Martins, C.M., De Carvalho, N.S., Teixeira, J.C., de Borba, P.C., Sanchez, N., et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccines Immunother 10:8 (2014), 2147–2162, 10.4161/hv.29532.
18. 18 Van den Broek, I.V.F., van Aar, F., Van Oeffelen, A.A.M., Op de Coul, E.L.M., Woestenberg, P.J., Heijne, J.C.M., et al. Sexually tranmitted infections in the Netherlands in 2015. 2016, National Institute for Public Health and the Environment, Bilthoven 2016-0027.
19. 19 Rondy, M., van Lier, A., van de Kassteele, J., Rust, L., de Melker, H., Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine 28:9 (2010), 2070–2075, 10.1016/j.vaccine.2009.12.042.
20. 20 Kasting, M.L., Shapiro, G.K., Rosberger, Z., Kahn, J.A., Zimet, G.D., Tempest in a teapot: a systematic review of HPV vaccination and risk compensation research. Hum Vaccines Immunother 12:6 (2016), 1435–1450, 10.1080/21645515.2016.1141158.
21. 21 Aubin, F., Pretet, J.L., Jacquard, A.C., Saunier, M., Carcopino, X., Jaroud, F., et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 47:5 (2008), 610–615, 10.1086/590560.
22. 22 Sturegard, E., Johansson, H., Ekstrom, J., Hansson, B.G., Johnsson, A., Gustafsson, E., et al. Human papillomavirus typing in reporting of condyloma. Sex Transm Dis 40:2 (2013), 123–129, 10.1097/OLQ.0b013e31827aa9b3.
23. 23 Hawkins, M.G., Winder, D.M., Ball, S.L., Vaughan, K., Sonnex, C., Stanley, M.A., et al. Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata. Virol J, 10, 2013, 137, 10.1186/1743-422X-10-137.
24. 24 Ball, S.L., Winder, D.M., Vaughan, K., Hanna, N., Levy, J., Sterling, J.C., et al. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol 83:8 (2011), 1345–1350, 10.1002/jmv.22111.
25. 25 Harari, A., Chen, Z., Burk, R.D., Human papillomavirus genomics: past, present and future. Curr Probl Dermatol 45 (2014), 1–18, 10.1159/000355952.
26. 26 Halloran, M.E., Longini, I.M., Struchiner, C., Gail, M., Krickeberg, K., Samet, J., Tsiatis, A., Wong, W., (eds.) Design and analysis of vaccine studies, 2010, Springer, New York.
27. 27 Mesher, D., Panwar, K., Thomas, S.L., Beddows, S., Soldan, K., Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open, 6(2), 2016, e009915, 10.1136/bmjopen-2015-009915.
28. 28 Cameron, R.L., Kavanagh, K., Pan, J., Love, J., Cuschieri, K., Robertson, C., et al. Human papillomavirus prevalence and Herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerg Infect Dis 22:1 (2016), 56–64, 10.3201/eid2201.150736.
29. 29 Petras, M., Adamkova, V., Impact of quadrivalent human papillomavirus vaccine in women at increased risk of genital warts burden: population-based cross-sectional survey of Czech women aged 16 to 40 years. Vaccine 33:46 (2015), 6264–6267, 10.1016/j.vaccine.2015.09.071.